SCHEMBL3674329

SCHEMBL3674329

O=C(NCCc1cccc(Cl)c1)c1ccc(N2CCN(C(=O)CC3CCCCC3)CC2)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.54
ALDH1A1 P00352 5/20 0.54
RAB9A P51151 5/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
MAPT P10636 2/20 0.54
LMNA P02545 1/20 0.54
TSHR P16473 1/20 0.54
KDM4E B2RXH2 3/20 0.51
HPGD P15428 2/20 0.51
TP53 P04637 1/20 0.51
HTT P42858 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HSD17B10 Q99714 1/20 0.50
SCD O00767 1/20 0.49
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
KMT2A Q03164 1/20 0.48
CXCR3 P49682 1/20 0.45
ROCK2 O75116 1/20 0.44
NAMPT P43490 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3673513 0.92 NPC1 (0.52) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL3668453 0.90 ALDH1A1 (0.67) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL3670373 0.85 ALDH1A1 (0.58) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL3666094 0.84 ALDH1A1 (0.59) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL3666245 0.83 NPC1 (0.53) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL3672166 0.83 SCD (0.58) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL3671518 0.82 SMN1; SMN2 (0.52) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL1330392 0.82 RAB9A (0.60) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL3672179 0.82 NPC1 (0.51) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL3670096 0.82 ALDH1A1 (0.53) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP claimed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US claimed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US claimed
EP-2266566-A2 Nicotinamide derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2010-12-29 EP disclosed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US disclosed
US-20070087363-A1 Therapeutic methods, compounds and compositions MYRIAD GENETICS, INCORPORATED (US) 2007-04-19 US disclosed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents NAMPT, NNT, NNMT NPC1 94/4885ALDH1A1 1127/4885RAB9A 1717/4885
US-20070087363-A1 Therapeutic methods, compounds and compositions APP, BACE1, PSEN1 NPC1 31/4885ALDH1A1 3898/4885RAB9A 1976/4885
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS NAMPT, NNT, NNMT NPC1 94/4885ALDH1A1 1127/4885RAB9A 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.